UNSPSC 51453502: Nitazoxanide

This classification denotes an antiprotozoal agent with the molecular formula C12H9N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SOA12P041N, chemically known as salicylamide, n-(5-nitro-2-thiazolyl)-, acetate (ester) but generally known as nitazoxanide, which bears US NIH Compound Identifier 41684. European Medicines Agency schedules Nitazoxanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09311MIG.

UNSPSC 51453502 Nitazoxanide, a Commodity code, nominally designates a single antiparasitic pharmaceutical product, but recent state and local solicitations show little activity directly aligned with nitazoxanide procurement. The most recent opportunities in the dataset—including Seminole County's naloxone and drug deactivation system bid, Tampa's medical and first aid supplies IFB for fire rescue, Texas HHS's therapeutic pharmacy initiative RFI, and Minnesota's multistate cooperative pharmaceutical RFP—involve broader pharmaceutical, OTC, and emergency medical supply sourcing with no explicit mention of nitazoxanide. State and local governments procuring under this code appear to be health departments, county health systems, fire and rescue divisions, and cooperative purchasing consortiums that serve multiple jurisdictions, though the current opportunity set does not demonstrate sustained demand specifically for nitazoxanide.

Geographic activity in the recent dataset spans Florida (Seminole County), Texas (HHS Commission), Florida again (Tampa), and Minnesota with multistate reach (Minnesota's MMCAP serving participating states including Oregon), reflecting scattered rather than concentrated regional demand. Representative opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone annually with a July 26, 2023 response deadline, Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies with a March 13, 2026 deadline and an estimated contract value of $700,000, and Minnesota MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. The code shows minimal current relevant activity; procurement professionals should verify whether opportunities labeled under this commodity code represent misclassification or genuine nitazoxanide demand before pursuing.